Steve Mahoney is Viridian’s President and Chief Executive Officer and a member of the Board of Directors. Steve has more than two decades of experience in a variety of operational, financial, commercial, legal and transactional roles in companies of different sizes and stages. He has been successful scaling organizations from founding team through commercial stage.
Prior to joining Viridian, Steve was the Chief Financial and Operating Officer of Magenta Therapeutics, where he drove operational excellence and disciplined capital allocation to high priority programs. Previously, Steve was part of the founding team of Kiniksa Pharmaceuticals, where he served as President and Chief Operating Officer. Prior to Kiniksa, he was Chief Commercial Officer of Synageva Biopharma, a company focused on ultrarare diseases, where he held roles of increasing responsibility in operations, commercial launch preparation, legal and corporate development. Steve was also a commercial attorney with Genzyme Corporation for approximately ten years. Prior to Genzyme, Steve was a corporate attorney with Mintz Levin.
Steve received his M.B.A. from Boston College’s Carroll School of Management, a J.D. from Boston College Law School, and a B.A. from Colorado College. He serves on the board of directors of Vesselon, Inc., a private company.
What is Stephen F. Mahoney's net worth?
The estimated net worth of Stephen F. Mahoney is at least $694.64 thousand as of September 27th, 2024. Mr. Mahoney owns 21,400 shares of Viridian Therapeutics stock worth more than $694,644 as of December 5th. This net worth approximation does not reflect any other assets that Mr. Mahoney may own. Learn More about Stephen F. Mahoney's net worth.
How old is Stephen F. Mahoney?
How do I contact Stephen F. Mahoney?
Has Stephen F. Mahoney been buying or selling shares of Viridian Therapeutics?
Stephen F. Mahoney has not been actively trading shares of Viridian Therapeutics during the last quarter. Most recently, on Friday, September 27th, Stephen F. Mahoney bought 21,400 shares of Viridian Therapeutics stock. The stock was acquired at an average cost of $23.33 per share, with a total value of $499,262.00. Following the completion of the transaction, the chief executive officer now directly owns 21,400 shares of the company's stock, valued at $499,262. Learn More on Stephen F. Mahoney's trading history.
Who are Viridian Therapeutics' active insiders?
Are insiders buying or selling shares of Viridian Therapeutics?
During the last twelve months, Viridian Therapeutics insiders bought shares 1 times. They purchased a total of 454,545 shares worth more than $9,999,990.00. The most recent insider tranaction occured on October, 23rd when Director Fairmount Funds Management Llc bought 454,545 shares worth more than $9,999,990.00. Insiders at Viridian Therapeutics own 1.6% of the company.
Learn More about insider trades at Viridian Therapeutics. Information on this page was last updated on 10/23/2025.
